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Abstract
Background: Parkinson’s disease (PD) is a chronic neurological disorder 
characterized by the loss of dopaminergic neurons in the substantia 
nigra pars compacta. The oxidative stress and inflammation, among 
other factors, are involved in the mechanisms of cell death in PD. We 
studied the neuroprotective properties of minocycline (Mino), focusing 
on its behavioral, neurochemical and immunohistochemical effects. 
Besides, Mino effects were also studied on an in vitro model of PD, 
as well as on the release of MPO in human neutrophils, and also its 
antioxidant activity. 
Methods: We used in vivo (unilateral injection of 6-OHDA into the 
right striatum) and in vitro (SH-SY5Y cells) models of PD. For the in 
vivo model, male Wistar rats were divided into the following groups: 
sham-operated (SO), 6-OHDA-lesioned and untreated and 6-OHDA-
lesioned and treated with Mino (10 and 25 mg/kg, p.o., 7 days). The 
animals were evaluated for behavioral, neurochemical and immuno-
histochemistry alterations. We also focused on Mino cytoprotective 
effects, as evaluated by its antioxidant and anti-inflammatory effects 
(nitrite determination and MPO release). 
Results: Mino (10 and 25 mg/kg, p.o.) significantly reversed the de-
crease in striatal DA and DOPAC contents, the alteration in apomor-
phine-induced rotational behavior and the locomotor activity observed 
in 6-OHDA-lesioned rats, indicative of neuroprotection. Besides, it 
decreased the immunoreactivity for TNF-alpha in the hippocampus. 
In SH-SY5Y cells, Mino increased cells viability, as evaluated by the 
MTT assay, and significantly decreased the high nitrite levels observed 
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Introduction
Parkinson’s disease (PD) is a progressive neurode-
generative disorder characterized by loss of dopa-
minergic (DA) neurons in the substantia nigra pars 
compacta. The impaired production and secretion 
of dopamine cause symptoms, including bradykine-
sia, tremor, rigidity and other motor and cognitive 
problems [1]. PD is a common neurodegenerative 
disorder, associated with substantial morbidity, in-
creased mortality and high economic burden [2]. 
A major problem in PD is the complexity of its onset. 
Pathways including protein aggregation, defects in 
the ubiquitin-proteasome system, mitochondrial 
damage, and oxidative and nitrosative stresses can 
contribute to the loss of dopaminergic neurons 
[3]. While different mechanisms, including environ-
mental toxins and genetic factors initiate neuronal 
damage in the substantia nigra and striatum of 
PD patients, there is evidence that the activation 
of neuroinflammatory cells aggravates this neuro-
degenerative process [4]. Furthermore, inflamma-
tion is a neuropathological feature of parkinsonian 
brains and of experimental models of the disease. 
Besides, activated glial cells contribute to the neu-
rodegenerative process, through the production of 
toxic molecules [5]. 
Evidences have indicated that, in both patients and 
experimental models of PD, neuroinflammation ap-
pears as a ubiquitous finding [6]. Furthermore, the 
immunohistochemical demonstration of reactive 
microglia and activated components suggests that 
chronic inflammation occurs in PD brain regions, 
and the involvement of neuroinflammatory process-
es in nigral degeneration has gained attention [7]. 
Post-mortem examination of human subjects ex-
posed to MPTP revealed the presence of activated 
microglia, decades after drug exposure, suggesting 
that even a brief pathogenic insult can induce an in-
flammatory response [8]. The iNOS expression was 
shown to be up-regulated in the substantia nigra 
of PD patients, but not of age-matched controls 
[9], suggesting that glial activation and the resulting 
release of NO may contribute to the chronic neuro-
degeneration that characterizes PD. The neurotoxin 
6-hydroxydopamine (6-OHDA), similarly to MPTP, 
is largely used as a model of PD. It is known to 
in the cells after 6-OHDA-induced cytotoxicity. Mino presented anti-
inflammatory and antioxidant effects as evaluated by inhibition of 
MPO release (an inflammatory marker) on human neutrophils and 
DPPH assay. 
Conclusion: Minocycline exerts neuroprotective effects in vivo and in 
vitro, decreasing dopaminergic cell loss, through mechanisms that are 
a consequence of Mino anti-inflammatory and antioxidant properties, 
pointing out to its potential application for the treatment of neurode-
generative diseases as PD. 
Key Words: Minocycline, neuroprotection, Parkinson’s disease, inflam-
mation, oxidative stress.
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cause inhibition of the mitochondrial complex I and 
oxidative stress, formed via DA oxidation [10, 11]. 
However, the exact mechanism by which 6-OHDA 
elicits its neurotoxic effects is not fully elucidated, 
although studies implicate a role for oxidative me-
diators [12, 13].
Minocycline (Mino) is a tetracycline exerting anti-
inflammatory effects, distinct from its antimicrobial 
action [14]. The drug is known to protect against 
brain ischemia [15, 16] associated with reduced ac-
tivation in microglia and inhibition of induction of 
the IL-1beta-converting enzyme (ICE) m-RNA. This 
suggests that Mino may function by reducing cy-
totoxic properties of microglia, triggered either by 
ischemia or by excitotoxicity [17]. In addition, Mino 
inhibits MMP, superoxide production from neutro-
phils, and iNOS expression in human cartilages and 
murine macrophages [18, 19, 20].
The objectives of the present study were to in-
vestigate the neuroprotective action of Mino on a 
6-OHDA-induced model of PD in rats. The focus 
was on behavioral alterations in untreated and Mi-
no-treated 6-OHDA-lesioned animals, on measure-
ments of striatal levels of DA and its metabolite 
DOPAC, as well as immunohistochemistry assays for 
TNF-alpha in the hippocampus. Besides, the effects 
of Mino on cell viability and nitrite concentrations 
in SH-SY5Y cells, on the release of MPO (an inflam-
mation marker) from human-stimulated neutrophils, 
and the DPPH assay for antioxidant activities were 
also investigated. 
Materials and Methods
Drugs and Reagents
6-Hydroxydopamine hydrochloride (6-OHDA), apo-
morphine and standard monoamines were pur-
chased from Sigma, USA. Minocycline was from Ga-
lena Laboratories, São Paulo, Brazil. Ketamine was 
purchased from König Laboratories (Buenos Aires, 
Argentina) and xylazine from Vetbrands Laboratory 
(São Paulo, Brazil). All other reagents were of ana-
lytical grade.
Animals
Adult male Wistar rats (260-280 g) from the Animal 
House of the Faculty of Medicine Estácio of Juazeiro 
do Norte (FMJ) were kept on a 12 h light/12 h dark 
cycle, with free access to water and standard food. 
All experiments were performed according to the 
Guide for the Care and Use of Laboratory Animals, 
from the US Health and Human Services Depart-
ment. The protocol was approved by the Ethics 
Committee on Animal Experimentation, of the Fac-
ulty of Medicine Estácio of Juazeiro do Norte, Brazil. 
In vivo studies: experimental protocol  
and behavioral tests
The animals were anesthetized with ketamine (30 
mg/kg, i.p.) and xylazine (25 mg/kg, i.p.), and re-
ceived two unilateral stereotaxic injections of 12 μg/
μL 6-OHDA each, containing 0.2 mg/mL L-ascorbic 
acid, into the right striatum, according to the fol-
lowing coordinates starting from bregma [21]: AP 
0.5/0.9, LL 2.5/2.7, DV 5.0/6.5. Sham-operated (SO) 
animals received vehicle, and were used as controls. 
The treatment with Mino (10 and 25 mg/kg, i.p.) 
started 1 h before the stereotaxic surgery (after the 
6-OHDA-induced lesion), and continued daily for 7 
days. Two weeks after the 6-OHDA injection, the 
behavior was assessed by monitoring body rotations 
induced by apomorphine (1 mg/kg, s.c.) when the 
number of net rotations (the number of 360° con-
tralateral turns) was recorded for 60 min. The uni-
lateral destruction of dopaminergic neurons causes 
a chemical imbalance of the brain content of this 
neurotransmitter. Because of this asymmetry, the 
administration of a dopamine agonist as apomor-
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phine causes stimulation of intact dopamine neu-
rons in the unaffected brain hemisphere. This is be-
haviorally manifested by locomotion in the direction 
of the unaffected hemisphere, making the animal to 
run in circles. The quantification of circling behavior 
is used to access the efficacy of drugs potentially 
useful for the treatment of PD [22]. 
The animals were also submitted to the open field 
test, in order to evaluate their locomotor activity 
(usually affected in experimental models of PD), and 
at the next day were sacrificed, the striatal tissue 
collected and stored at −70°C until use. 
Monoamine levels determination
For measurements of dopamine and its metabolite 
(3,4 dihydroxyphenylacetic acid - DOPAC), striata 
from both sides of 6-OHDA-lesioned (untreated or 
treated with Mino) and unlesioned sham-operated 
groups were used to prepare 10% homogenates. 
Homogenates were sonicated in 0.1 M HClO4, for 
30 s, centrifuged at 4°C for 15 min at 15,000 rpm, 
and the supernatants were filtered (0.2 μm, Mil-
lipore). Twenty-microliter samples were then in-
jected into a high-performance liquid chromatog-
raphy (HPLC) column. The mobile phase was 0.163 
M citric acid, pH 3.0, containing 0.02 mM EDTA 
with 0.69 mM sodium octanesulfonic acid (SOS), 
as an ion pairing reagent, 4% v/v acetonitrile and 
1.7% v/v tetrahydrofuran. The monoamines were 
electrochemically detected, using an amperometric 
detector (Shimadzu, Japan), by oxidation on a glassy 
carbon electrode at 0.85 V relative to the Ag–AgCl 
reference electrode. Their concentrations were de-
termined by comparison with standards injected 
into the HPLC column at the day of experiment, 
and the values expressed as ng/mg tissue.
Immunohistochemistry for TNF-alpha  
in the hippocampus
Hippocampal slices from SO, untreated 6-OHDA-
lesioned and 6-OHDA-lesioned rats treated with 
Mino (10 and 25 mg/kg) were washed three times 
with 0.05 M Tris buffer (TB, pH 7.6). Then, the en-
dogenous peroxidase was blocked with 3% H2O2 
in 10% methanol in TB, for 15 min. The slices were 
washed three times again with TB and pre-incubat-
ed with 5% normal goat serum (NGS), for 30 min 
in 0.3% Triton, followed by the incubation with the 
primary TNF-alpha antibody (diluted in 2% NGS/TB), 
overnight at 4°C, according to the manufacturer’s 
instructions (Calbiochem, Nottingham, UK). Then, 
after three washings with TB, the slices were in-
cubated with the secondary antibody (biotinylated 
goat anti-rabbit IgG, 1:200, DAKO) for 2 h, washed 
three times again with TB, and revealed with 0.05% 
diaminobenzidine in 0.03% H2O2, for 10 min. After 
a final washing with distilled water, the slices were 
mounted for microscopy examination. 
In vitro studies with SH-SY5Y 
dopaminergic cells: cell culture
The SH-SY5Y cell line from human neuroblastoma 
has become a popular cell model for PD research, 
because this cell line possesses many characteristics 
of DAergic neurons. For example, these cells express 
tyrosine hydroxylase and dopamine-beta-hydroxy-
lase, as well as the dopamine transporter [23]. The 
cells were cultivated in 25 cm2 culture flasks (from 
Corning, USA) with a 50 mL volume, in 1:1 DMEM/
F12 medium (Gibco, USA), containing 10% bovine 
fetal sera and 1% penicillin/streptomycin. The cells 
were then maintained in the oven at 37°C and a 
5% CO2/95% O2 atmosphere. The cell growth was 
followed by observation on an inverted microscope. 
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MTT Assay in SH-SY5Y cells 
Minocycline neuroprotection was evaluated by 
the MTT assay, based on the conversion of the 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT) yellow salt to the blue formazan 
compound. This conversion only occurs in metaboli-
cally active and viable cells, by the action of the suc-
cinate dehydrogenase enzyme present in mitochon-
dria. This permits the indirect quantification of the 
percentage of viable cells [24]. For the assay, mono-
layers of SH-SY5Y cells were plated in 96 wells, at 
a 0.7 x 105 cells/mL density. The cells were cultured 
for 5 days and then Mino (at concentrations of 0.1, 
1 and 10 μg/mL, based on previous experiments) 
was added 1 h before 6-OHDA (12.5 μg/mL). After 
24 h incubation in the oven, at 37°C and a 5% 
CO2, 95% O2 atmosphere, the suspension of cells 
culture was centrifuged (1500 rpm/15 min) and the 
supernatant discarded. Then, 200 mL of a 10% MTT 
solution (in 1:1 DMEM/F12 medium) were added 
to each well, followed by incubation for 3 h and 
centrifugation (3000 rpm/10 min). The supernatant 
was again discarded, and the formazan blue pellet 
resuspended; in 150 μL DMSO and shaken for 10 
min until complete dissolution. The quantification of 
the reduced MTT salt was carried out with a plaque 
reader at 595 nm. 
Nitrite determination in SH-SY5Y cells
The Griess reagent provides a simple and well char-
acterized colorimetric assay for nitrites, and nitrates 
that have been reduced to nitrites, with a 100 
nM detection limit. After cells incubation, the ni-
trite concentration was determined by the method 
of Green et al., 1981 [25]. For this, 100 mL Griess 
reagent (1% sulphanilamide/0.1% N-(1-naphthyl)-
ethylenediamine hydrochloride/1% H3PO4/distilled 
water, 1:1:1:1) were added to 100 mL cell culture 
supernatant, followed by 10 min incubation at room 
temperature. The standard curve was made with 
concentrations of NaNO2, ranging from 0.75 to 100 
mM under the same conditions. Blanks were pre-
pared by the addition of 100 mL Griess reagent to 
100 mL culture medium, and the absorbance deter-
mined with a plaque reader at 560 nm.
Myeloperoxidase release from human 
neutrophils
Myeloperoxidase (MPO) is an enzyme stored in azu-
rophilic granules of polymorphonuclear neutrophils 
and macrophages, and released into extracellular 
fluid in the setting of inflammatory process. It is 
involved in oxidative stress and inflammation, and 
thus considered as a marker for systemic inflam-
mation. Following Lucisano and Mantovani, 1984 
[26], 2.5 x 106 human leukocytes were suspended 
in buffered Hank’s balanced salt solution, contain-
ing calcium and magnesium. The preparations usu-
ally contained predominantly neutrophils (85.0 ± 
2.8%), and the cell viability, as determined by the 
Trypan blue test, was 97.7 ± 0.94%. The cells were 
incubated with Mino (0.001 to 1 mg/mL) or indo-
methacin at 35.7 µg/mL (Indo, as standard), for 15 
min at 37ºC. Human neutrophils were stimulated 
by the addition of phorbol myristate acetate (PMA, 
0.1 mg/mL), for 15 min at 37ºC. The suspension 
was centrifuged for 10 min at 2000 x g at 4ºC. 
Aliquots (50 μL) of the supernatants were added 
to phosphate-buffered saline (100 mL), phosphate 
buffer (50 mL, pH 7.0) and H2O2 (0.012%). After 5 
min at 37ºC, TMB (1.5 mM, 20 mL) was added, and 
the reaction was stopped by 30 mL sodium acetate 
(1.5 M, pH 3.0). The absorbance was determined 
using a spectrophotometer (620 nm) 
Diphenyl-2-picriylhydrazyl  
(DPPH)-scavenging activity 
The stable free radical DPPH (2,2-diphenyl-1-picryl-
hydrazyl-hydrate) is used as an antioxidant assay, 
based on electron-transfer that produces a violet 
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solution in ethanol. This free radical is reduced in 
the presence of an antioxidant molecule, giving rise 
to colorless ethanol solution. This assay provides an 
easy and rapid way to evaluate antioxidants by spec-
trophotometry. Minocycline and alpha-tocopherol 
(as reference) were evaluated by the DPPH assay 
[27]. Briefly, an aliquot (0.1 mL) of Mino (1 to 50 µg/
mL) or alpha-tocopherol (5 or 50 mg/mL) was mixed 
with 3.9 mL DPPH solution (0.3 mM). The mixture 
was vortexed for 1 min and then left standing at 
room temperature for 30 min. Finally, the absor-
bance of the resulting solution was read spectro-
photometrically (Beckman Instruments Inc.) at 517 
nm.
Statistical Analyses
For monoamine contents, the data were analyzed 
by the Student’s t test, when comparison was per-
formed between right and left striata from the 
same group, and by One-way ANOVA followed by 
Newman-Keuls as a post hoc test, for comparing 
the same striatal side among groups. Identical pro-
cedure was used for all other statistical analyses. 
Results
Effects of the minocycline (Mino) treatment on stria-
tal DA and its metabolites in 6-OHDA-lesioned rats 
The 6-OHDA-lesioned right striata showed a 63% 
decrease in DA concentrations, as compared to 
the unlesioned left striata of the same group. 
This decrease was lower in th 6-OHDA-lesioned 
right striata of Mino-treated rats, especially in the 
6-OHDA+Mino25 group whose reduction was only 
20%, as compared to its left side. The SO group 
showed no change in DA content (Fig. 1A) The 
percentage reductions of DOPAC levels in the right 
striata of the 6-OHDA-lesioned group were around 
Figure 1. Minocycline (Mino: 10 and 25 mg/kg, i.p.) significantly reversed the DA (A) and DOPAC (B) contents in the lesioned right striatum 
(R), as related to its unlesioned left side (L) and mainly to the right side of the 6-OHDA-lesioned untreated group. The values are means 
± S.E.M. from 6 to 14 animals per group. SO = sham-operated group. (A): a. p < 0.001 vs. 6-OHDA L; b. p < 0.05 vs. 6-OHDA R; c. p < 
0.05 vs. 6-OHDA + Mino10 L; d. p<0.001 vs. 6-OHDA R. (B): a. p<0.001 vs. 6-OHDA L; b. p<0.05 vs. 6-OHDA + Mino10 R; c. p<0.05 
vs. 6-OHDA + Mino25 R; d. p<0.001 vs. 6-OHDA + Mino10 R; e. p<0.01 vs. 6-OHDA L; f. p<0.01 vs. 6-OHDA + Mino25 L.
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60%, in relation to its unlesioned left side, while 
these changes were lower after Mino treatments 
(50 and 23% decreases after the doses of 10 and 
25 mg/kg, respectively). No significant alterations in 
DOPAC contents were observed in either side of the 
striata in the SO group (Fig. 1B). 
Apomorphine-induced rotational behavior 
in 6-OHDA-lesioned rats, without and 
with minocycline treatments
While 6-OHDA-lesioned and untreated rats pre-
sented high numbers of contralateral rotations 
(296.7±32.12 turns/h), this effect was significantly 
reversed after Mino treatments (6-OHDA+Mino10: 
72.6±20.05 turns/h; 6-OHDA+Mino25: 110.5±20.20 
turns/h). On the other hand, almost no rotation was 
shown by the SO group (12.8±6.53 turns/h) (Fig. 2).
Figure 2. Minocycline (Mino: 10 and 25 mg/kg, i.p.) significantly 
reversed the increased apomorphine-induced rotational behavior, 
evaluated by the number of contralateral rotations for 1 h, as 
compared to the 6-OHDA-lesioned untreated group. As expected, 
very few rotations were seen in the sham-operated (SO) group. The 
values are means ± S.E.M. from 17 to 22 animals per group. a. p 
< 0.001 vs. 6-OHDA. Exploratory behavior in the open field 
test 
The 6-OHDA-lesioned rats showed a significant 
decrease of 64% in locomotor activity (6.7±1.92), 
compared to the SO group (18.6±1.85), as evalu-
ated by the number of crossings/5 min. The treat-
ment of the 6-OHDA-lesioned group with the two 
doses of Mino reverted this effect, bringing values 
close to those of the SO group with the higher dose 
(6-OHDA+Mino25: 15.1±3.38) (Fig. 3).
Minocycline (Mino) decreases the 
immunoreactivity for TNF-alpha in the rat 
hippocampus
Figure 4 shows representative photomicrographs 
of dentate gyrus where the untreated 6-OHDA-le-
sioned group presents a high immunoreactivity for 
TNF-alpha. This effect was in great part reversed by 
Mino treatments (6-OHDA+Mino 10 or 25). On the 
other hand, few immunopositive cells for TNF-alpha 
were seen in the SO group. 
Figure 3. Minocycline (Mino: 10 and 25 mg/kg, i.p.) partially 
reversed the decreased locomotor activity (number of crossings/5 
min) observed in 6-OHDA-lesioned untreated rats. However, the 
locomotor activity was higher in the controls (sham-operated group 
= SO) but not statistically different from the 6-OHDA+Mino25 
group. The values are means ± S.E.M. from 7 to 10 animals per 
group. a. p < 0.05 vs. SO. 
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Figure 4. Minocycline (10 and 25 mg/
kg) decreases the number of TNF-alpha 
immunopositive cells in the hippocampus 
(dentate gyrus), as related to the untreated 
6-OHDA-lesioned group. A: SO; B: 
untreated 6-OHDA; C: 6-OHDA+Mino10; 
D: 6-OHDA+Mino25 (200X magnification).
Figure 5. Concentration-response curve of minocycline (Mino: 1 to 100 μg/mL) in SH-SY5Y cells, showing a cytotoxic effect at concentrations 
equal to or higher than 100 μg/mL (A). 6-OHDA at the concentration of 12.5 μg/mL decreased cell viability by 64%, as related to controls. 
The values are means ± S.E.M. from 3 to 12 samples. a. p < 0.05 to 0.001 vs. controls; b. p < 0.05 to 0.01 vs. 6-OHDA 12.5. (B) Minocycline 
(Mino: 0.1, 1 and 10 μg/mL) significantly and dose-dependently protected SH-SY5Y cells from death, after their exposure to the 6-OHDA 
neurotoxin (12.5  μg/mL), as evaluated by the MTT assay. While 6-OHDA decreased by 66% the percentage of cell viability, Mino partially 
blocked the neurotoxin effect, bringing values closer to those of controls. a. p < 0.001 vs. controls; b. p < 0.05 vs. 6-OHDA 12.5.
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In vitro studies
Effects of minocycline on cell viability, as 
evaluated by the MTT assay in SH-SY5Y 
cells
Fig. 5A shows the Mino concentration-response 
curve, demonstrating that it decreases cells viabil-
ity at concentrations equal or higher than 100 μg/
mL, an indicative of cytotoxicity. A 57% decrease 
was observed in SH-SY5Y cells viability, after their 
exposure to the 6-OHDA neurotoxin (12.5 μM), as 
related to the untreated cells (controls). The cell 
treatment with Mino (0.1, 1 and 10 μg/mL) par-
tially reversed the neurotoxin effect, improving cells 
viability which decreased by only 33 and 15% with 
Mino, at the concentrations of 1 and 10 µg/mL, 
respectively. The lower dose (0.1 μg/mL) showed 
no cytoprotective effect (Fig. 5B).
Effects of minocycline on nitrite 
concentrations in SH-SY5Y cells
The SH-SY5Y cells exposure to 6-OHDA (12.5 μM) 
significantly increased the nitrite concentration by 
sixfold, as compared to the unexposed cells (con-
trols). On the other hand, this neurotoxin effect was 
almost completely reversed after the addition of 
Mino, at concentrations of 0.1, 1 and 10 μg/mL. 
Under these conditions, the nitrite concentrations 
increased only from 1.5- to 1.9-fold (Fig. 6). 
Minocycline inhibits MPO release in 
human neutrophils 
Figure 7 shows a concentration-dependent effect 
of Mino on MPO release by human neutrophils. 
While only 8% inhibition was achieved in the pres-
ence of Mino, at 0.001 µg/mL, the percentage in-
hibition increased to almost 70%, at the concen-
Figure 6. Minocycline (Mino: 0.1, 1 and 10 μg/mL) completely 
reversed the increased nitrite levels observed in SH-SY5Y cells, after 
their exposure to 6-OHDA, and the values (means ± S.E.M. from 4 
to 15 samples) were very close to those of controls. a. p < 0.05 vs. 
controls; b. p<0.001 vs. 6-OHDA 12.5.
Figure 7. Minocycline (µg/mL) inhibits the myeloperoxidase (MPO) 
release from human neutrophils, at 1 µg/mL concentration, and this 
effect was similar to that observed in the presence of indomethacin 
(Indo, 35.7 µg/mL) used as reference. Assays were performed in at 
least quadruplicated samples. a. and b. vs. all other four groups, 
p<0.0001. 
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tration of 1 µg/mL. This value was similar to that 
observed in the presence of indomethacin (Indo, 
35.7 µg/mL), used as reference.
 
Scavenging activity of minocycline, as 
evaluated by the DPPH assay
Data on the antioxidant effect of Mino, at concen-
trations ranging from 1 to 50 µg/mL, are shown in 
Fig. 8. In this assay, a significant effect of Mino was 
observed only with the concentration of 50 µg/mL, 
comparable to that observed in the presence of vita-
min E (used as reference), at a similar concentration.
Discussion 
Our data demonstrated that minocycline (Mino) 
can effectively protect striatal dopaminergic neu-
rons from the effects of the 6-OHDA neurotoxin, 
Figure 8. Minocycline (µg/mL) presents a radical scavenger activity, 
as evaluated by the DPPH assay. A significant effect was observed 
at a concentration of 50 µg/mL, similar to that observed in the 
presence of vitamin E used as reference. Assays were performed 
at least in quadruplicated samples. a. and b. p<0.0001 vs. controls 
and Vitamin E 50.
in rats which is a widely used model for Parkin-
son’s disease. The neuroprotective effect of Mino 
(10 and 25 mg/kg) was observed after its intraperi-
toneal administration for 7 days. Although there are 
many studies showing the neuroprotective effects 
of Mino on various experimental models, such as 
cerebral ischemia [28, 29, 30, 31] among others, 
those on PD models are fewer [32, 33]. 
We showed, in the model of unilateral striatal 6-OH-
DA-lesioned rats, that the increased apomorphine-
induced rotation turns were significantly decreased 
by Mino, indicative of a neuroprotective effect 
and less degeneration of dopaminergic neurons. 
The unilateral injection of 6-hydroxydopamine (6-
OHDA) into the right substantia nigra or striatum is 
known to produce an extensive loss of dopaminer-
gic cells. The imbalance in dopaminergic innervation 
between both sides results in a postural asymmetry, 
causing rotation away from the contralateral un-
lesioned side. Analyses of mitochondrial oxidative 
phosphorylation enzyme activities, in nigral tissue 
from 6-OHDA-lesioned rats, revealed a clear loss 
of complex I activity [34]. A deficit in mitochondrial 
complex I could conceivably contribute to cell death 
in parkinsonism, via free radical mechanisms, both 
directly by reactive oxygen species production and 
indirectly by the decreased ATP synthesis and en-
ergy failure.
Additionally, we showed that 6-OHDA significantly 
reduced DA contents in the lesioned right striatum, 
as compared to the unlesioned left striatum of the 
same experimental group. Mino treatments reversed 
the decreases in DA contents in the lesioned right 
striatum, compared to the 6-OHDA-lesioned right 
striatum of untreated rats, also suggesting that the 
drug presents a neuroprotective effect. A similar re-
sult was observed in DOPAC contents. 
The toxicity of 6-OHDA seems to be related to the 
production of ROS, including superoxide radicals, 
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hydrogen peroxide and hydroxyl radicals [35, 36, 
37]. The pronounced toxicity on DA neurons is 
due to the selective uptake of this toxin by the DA 
transporter (DAT) system, as well as the presence 
of monoamine oxidase (MAO) and low tolerance of 
the dopaminergic neuronal population to oxidative 
stress. Indeed, ROS and the oxidative stress have 
been pointed out as key factors in the pathogenic 
cascade, leading to loss of midbrain DA neurons in 
PD [38].
The intra-striatal administration of 6-OHDA has 
been found to induce a microglial reaction [39] that 
may participate in the progression or extension of 
neuronal loss caused by the neurotoxin. Minocy-
cline was demonstrated to protect nigral cells from 
MPTP and 6-OHDA toxicities [40]. This antibiotic (45 
mg/kg, i.p.) displayed beneficial effects against the 
striatal injection of 6-OHDA, and the subsequent 
nigral cell degeneration and microgliosis. Protec-
tion against this toxin has been also observed in 
vitro (41). The oral administration of Mino (60-120 
mg/kg, p.o., or 11-45 mg/kg, i.p.) blocked MPTP-
induced degeneration of dopamine neurons, as well 
as the loss of striatal dopamine and its metabolites, 
and mitigated the formation of nitrotyrosine. These 
effects were thought to be related to an inhibitory 
effect of Mino on microglial activation (42). 
Almost all the beneficial effects of Mino are related 
to an inhibitory activity on inflammation processes 
and/or apoptotic cell death, both phenomena be-
ing intimately related to neuronal degeneration [43]. 
Interestingly, Mino also protected dopaminergic 
neurons from the activation of microglia, induced 
by an injection of lipopolysaccharide (LPS) within 
the substantia nigra [44]. Accordingly, several stud-
ies showed that Mino reduces the expression of 
inducible nitric oxide synthase and subsequent ni-
tric oxide production, as well as caspase-1 activity/
expression, and thereby prevents the formation of 
IL-1beta [45, 46]. 
Mino also prevents oxidative protein modifications 
and damage in disease models associated with in-
flammatory glial activation and oxidative stress and, 
although the drug is assumed to act by preventing 
the up-regulation of pro-inflammatory enzymes, it 
has been shown that Mino acts by a direct chemi-
cal interaction with ROS [47]. Others suggested that 
the neuroprotective effects of Mino might be asso-
ciated with the mitigation of neuronal excitability, 
glutamate release and Ca2+ overloading [48].
We showed that decreased locomotor activity ob-
served in hemiparkinsonian rats was reversed after 
Mino treatment. A similar effect was seen in groom-
ing behavior. Previously, we demonstrated that isch-
emia-induced behavior alterations were reversed by 
Mino, and in this case all the observed parameters 
(locomotor activity, rearing and grooming behav-
iors) were equally affected [49]. It has been found 
that Mino, administered to mice after traumatic 
brain injury (TBI), attenuated microglial activation 
and reduced the brain lesion volume, as well as 
TBI-induced hyperactivity [50].
Chronic neuroinflammation is a typical feature in 
neurodegenerative diseases, including PD, in which 
TNF-alpha expression appears to be upregulated 
representing a valuable target for intervention [51, 
52, 53]. In addition, evidences indicate that TNF-
alpha may play a role in the selective vulnerability 
of the nigrostriatal pathway associated to dopami-
nergic neurotoxicity [54]. Minocycline is known to 
protect cells, via an anti-inflammatory mechanism 
[55], and a recent study demonstrated that it de-
creased brain TNF-alpha levels, as evaluated by a 
hypothermic cardiac arrest model in rats [56]. 
We showed a decreased immunoreactivity for TNF-
alpha in the hippocampus from 6-OHDA-lesioned 
rats after treatments with Mino, as related to the 
6-OHDA-lesioned and untreated group. Neuro-
pathological studies show that the hippocampus 
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is affected in PD, and hippocampal degeneration 
could be responsible for the patient’s cognitive dys-
function [57]. Moreover, other data suggest interac-
tions between the dopaminergic system and hippo-
campus, in synaptic plasticity, adaptive memory and 
motivated behavior [58], and that the declarative 
memory impairment in PD patients without demen-
tia may be predicted by the rate of microstructural 
alterations in the hippocampal formation [59]. Our 
findings may certainly contribute to the drug neu-
roprotective action.
We also demonstrated that Mino protected SH-
SY5Y cells against 6-OHDA cytotoxicity in a dose-
dependent manner, as evaluated by the MTT assay. 
As a matter of fact, the drug seems to exhibit a toxic 
action, at concentrations equal to or higher than 
a 100 μg/ml. Furthermore, Mino significantly de-
creased nitrite contents of cells previously exposed 
to 6-OHDA, indicating an antioxidant action. SH-
SY5Y cells are originated from human neuroblas-
toma and known to mimic many aspects of the do-
paminergic neuronal death observed in PD, caused 
by mitochondrial complex I neurotoxins [23, 49. 50]. 
The SH-SY5Y cell line has become a popular model 
for PD, for possessing many characteristic of dopa-
minergic neurons. Thus, these cells express tyrosine 
hydroxylase and dopamine-β hydroxylase, as well as 
the dopamine transporter (DAT).
Although it is accepted that 6-OHDA induces cy-
totoxicity in different cell types, the mechanisms 
involved are controversial, and among them the 
generation of ROS is the most accepted one [42, 
60, 61]. Thus, 6-OHDA can either undergo extracel-
lular auto-oxidation or intracellular enzymatic oxida-
tion through MAO B, yielding ROS, quinones and 
their degradation products [62]. It has been found 
that 6-OHDA induces mitochondrial fragmentation 
in SH-SY5Y cells [63]. These authors showed that 
6-OHDA-induced mitochondrial fragmentation is 
an early event, preceding the collapse of the mem-
brane potential and cytochrome c release in SH-
SY5Y cells. 
Minocycline was shown to inhibit iNOS expression 
and NO release, and to increase neuronal survival, 
as well as to inhibit the production of TNF-alpha 
mediated by LPS in glial cells [64]. These authors 
used Mino concentrations ranging from 1 to 20 nM, 
and found a maximal neuroprotective effect with-
out toxicity, at the concentration of 1 nM. 
Minocycline was able to significantly decrease the 
myeloperoxidase release from human neurotroph-
ils, at very low concentrations (0.1 µg/mL), and its 
effect was similar to that of indomethacin used as 
reference. Myeloperoxidase (MPO) is a hemopro-
tein abundantly expressed in polymorphonuclear 
leukocytes (neutrophils) and secreted during their 
activation. This enzyme has been proposed as a bio-
marker of inflammation, under several pathological 
conditions [65, 66, 67]. In addition, Mino presented 
an antioxidant activity in vitro, as evaluated by the 
DPPH assay.
Increasing evidence [68] indicates that both oxida-
tive stress and inflammation may play a fundamen-
tal role in the pathogenesis of PD, and minocycline 
was shown to prevent oxidative protein modifica-
tions and damage in disease models associated 
with inflammatory glial activation and oxidative 
stress [69]. Previously, we demonstrated a potent 
anti-inflammatory effect of Mino acutely admin-
istered in several models of inflammation [70]. In 
addition, Mino sub-chronically injected significantly 
reversed neurochemical and behavior alterations, in 
models of global ischemia and PD in rats [71]. Our 
data indicate that the anti-inflammatory and anti-
oxidant effects, besides the inhibitions of iNOS and 
TNF-alpha among other properties, could stimulate 
translational data from experimental studies to ran-
domized and well-designed clinical trials of neu-
roprotective agents as Mino, for new therapeutic 
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applications, especially those where inflammation 
plays a role [72]. We conclude that Mino may act 
as a dopaminergic agonist, and this effect together 
with the drug anti-inflammatory and antioxidant 
activities are probably responsible for its neuropro-
tective action. 
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